Blog

PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.

PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.

Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...

Creating a shared language for talking about tuberculosis has been identified by the Stop TB Partnership as being a constructive step towards achieving the United Nations political declaration to eliminate TB by 2030.

Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report

The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.

Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.

Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech, developers of Actiphage - a rapid blood test for early-stage active tuberculosis - is partnering with the Rapid Research in...

New Chief Operating Officer brings experience of tuberculosis vaccine and precision medicine.

A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.

Sub-Saharan Africa is devastated by TB disease. Zambia, has a high TB/HIV burden – 59,000 people developed TB in 2020 and 15,000 died. There is a critical need for a non-sputum based rapid test for diagnosing TB disease.

Bacteriophages, viruses that infect and kill bacteria, offer the potential of a powerful tool for detecting and treating mycobacterial infections such as tuberculosis (TB), authors of a review in the journal Microorganisms* have reported.